Everyday Urology™ – Oncology Insights: From the Editor
From the Desk of the Editor: Volume 2, Issue 3
Petros Grivas’ cover article, Updates on Immunotherapy for Urothelial Cancer, not only succinctly reviews the five new approved immuno-oncology therapies (IO), aka checkpoint (PD pathway) inhibitors and their milestone clinical trials, but also offers guidance regarding treatment selection strategy as well as IO selection within the context of chemotherapeutic options. Additionally, he discusses a basis for monitoring efficacy of response, potential biomarkers and genomic markers predictive of patient benefit and also reviews the ongoing possibilities for combination strategies. Clearly, both advanced bladder and kidney cancer care information and subsequent
From the Desk of the Editor: Volume 2, Issue 2
From the Desk of the Editor: Volume 2, Issue 1
Our first issue of 2017 emphasizes a well-known, yet an evolving and important, theme: optimizing the successful multidisciplinary collaboration amongst oncologic physicians; and furthermore, the importance of patient involvement, also known as, patient-physician shared decision making (and assuredly, successful integrated care). This multidimensional approach to decision making and treatment has numerous advantages in all phases of the patient care experience, the physician expectation of successful genitourinary oncology outcomes, and efficiency for the healthcare ecosystem. The authors of our three featured articles in this issue include the specialties of: urology, cardiology and nuclear medicine.